N.J Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupportedThe company ...

The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it thinks ...

TEVAN.UL] failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva also boasts a compelling growth trajectory, with revenue expected to increase by 15% and EBIT by 30% from 2024 to 2028. Free cash flow yield, currently at 9.8%, is projected to exceed 16% by ...

The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.55% of the company’s stock. Teva ...

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could transform treatment options and reshape the market.

J.P. Morgan analyst Chris Schott maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares closed yesterday at $20.88. Discover top-rated stocks ...

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...